These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30644358)

  • 1.
    Lee E; Wongvipat J; Choi D; Wang P; Lee YS; Zheng D; Watson PA; Gopalan A; Sawyers CL
    Elife; 2019 Jan; 8():. PubMed ID: 30644358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
    Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
    Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
    Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
    Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
    Nadiminty N; Tummala R; Liu C; Yang J; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Aug; 12(8):1629-37. PubMed ID: 23699654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
    Shah N; Wang P; Wongvipat J; Karthaus WR; Abida W; Armenia J; Rockowitz S; Drier Y; Bernstein BE; Long HW; Freedman ML; Arora VK; Zheng D; Sawyers CL
    Elife; 2017 Sep; 6():. PubMed ID: 28891793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
    Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Okada T; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Free Radic Biol Med; 2024 Aug; 221():81-88. PubMed ID: 38762061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance.
    Culig Z; Puhr M
    Am J Pathol; 2024 Mar; 194(3):324-334. PubMed ID: 38104650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy.
    Geng H; Xue C; Mendonca J; Sun XX; Liu Q; Reardon PN; Chen Y; Qian K; Hua V; Chen A; Pan F; Yuan J; Dang S; Beer TM; Dai MS; Kachhap SK; Qian DZ
    Nat Commun; 2018 Nov; 9(1):4972. PubMed ID: 30478344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
    Ware KE; Somarelli JA; Schaeffer D; Li J; Zhang T; Park S; Patierno SR; Freedman J; Foo WC; Garcia-Blanco MA; Armstrong AJ
    Oncotarget; 2016 Aug; 7(31):50507-50521. PubMed ID: 27409172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
    Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
    Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
    Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
    Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.